Kushan Biswas

Another great insights from ZS Atlas Intelligence on how consumers choices around weight management can have notable impacts on their behaviors in other categories as well. In their analysis, Russell Evans, Eric Swank and Harmandir Singh Bhasin observed that GLP-1 users are more likely to increase consumption of water and “named” diets like keto while reducing consumption of sugar, alcohol and carbs. Also, GLP-1s may inadvertently inhibit key behavior changes required for long-term success such as tracking nutritional intake or participating in exercise. Fascinating landscape to explore!

27

1 Comment

🌟 **Excitement is Building for the 2025 J.P. Morgan Healthcare Conference!** 🌟 As we gear up for one of the most anticipated events in the healthcare industry, here are some key trends and topics I expect to be in the spotlight: 1. **Artificial Intelligence (AI)**: From drug discovery to personalized medicine, AI is revolutionizing healthcare. 2. **Gene Editing and CRISPR Technology**: Cutting-edge advancements paving the way for new therapies. 3. **Digital Health and Telemedicine**: Expanding telehealth services and remote patient monitoring. 4. **Aging Population and Chronic Disease Management**: Addressing the needs of an aging population and managing chronic diseases. 5. **Biosimilars and Biopharmaceuticals**: The impact of biosimilars on the market. 6. **Healthcare Equity and Access**: Driving efforts to reduce disparities and improve access to care. 7. **Mergers and Acquisitions (M&A)**: Industry consolidation and strategic deal-making. These topics reflect the ongoing evolution and innovation within our industry. Can't wait to see the exciting developments and insights that will emerge from the conference! #JPM2025 #HealthcareConference #HealthInnovation #AIinHealthcare #GeneEditing #DigitalHealth #HealthEquity #Biopharma #IndustryTrends

24

1 Comment

Apax Partners will sell India's Healthium Medtech to KKR https://ift.tt/Ozc1dh6 Apax Partners will sell India's Healthium Medtech to KKR By selecting Anish Bafna as CEO and Vishal Maheshwari as CFO, the firm strengthened its management team and added substantial industry knowledge with the backing of Apax Funds, setting Healthium up for success. The major international investment firm KKR stated on May 6 that it has signed final agreements to buy Healthium Medtech Ltd., a prominent Indian manufacturer of medical equipment, from a fund affiliate supervised by renowned global private equity consulting firm Apax Partners LLP. The news that KKR had emerged as the front-runner to purchase Healthium Medtech in a transaction that could value the company up to $850 million was originally reported by Moneycontrol on May 4. The purchase of a controlling stake in the Healthium group, which includes Healthium, will be carried out via a special purpose entity controlled by funds managed by KKR. Healthium is a medical device firm that was established in India in 1992 that develops, produces, and markets a wide variety of surgical products worldwide. Its extensive, superior portfolio offers enhanced wound closure, arthroscopy, and solutions to meet the demands of a broad range of surgeons. After acquiring Healthium in 2018, Apax Funds turned the local suture player into a leader in medical devices worldwide. By appointing Anish Bafna as CEO and Vishal Maheshwari as CFO, the firm strengthened its executive team and added extensive industry expertise, all with the backing of Apax Funds, setting Healthium up for expansion. Through internal R&D and M&A, Healthium expanded its range of products to include wound closure devices and consumables and made investments in new businesses, including arthroscopy and advanced wound care. Healthium increased its footprint from 50 to over 90 nations during this time. "Healthium has established itself as a major domestic manufacturer of medical devices with a great track record of providing high-quality products and a broad distribution network both in India and internationally under the leadership of Anish and his brilliant management team. Partner and head of KKR's India Private Equity Akshay Tanna stated, "We look forward to harnessing our global network and healthcare expertise to help accelerate its growth in this fast-growing sector while helping to scale its global business through both natural and artificial growth strategies." Apax, according to partner Steven Dyson, saw a chance to build a globally diversified MedTech platform by using Healthium's robust current portfolio. "We are pleased to have contributed to Healthium's development as India's top medical technology company by helping it with investments in R&D, production capacity, and portfolio diversification. We extend our gratitude to Anish, Vishal, and the team and wish them continued success. Healthium's CEO, Anish Bafna, said that the company ...

1

We have been all wondering when/how the venture investing will bounce back from its lows over the last 2 years. Well, this report by my colleague Jeffrey Grabow and his team may be an early indicator. (Word of caution to my fellow life sciences folks as the data captures all sectors) "Take five" headlines below: 1. VC-backed companies raised $42.9 billion in Q2 2024, an increase of 29% from the $33.3 billion raised in Q1 2024. 2. AI-related companies raised 37% of total VC this quarter, more than double Q1 2024. So, no one can predict how the trend would look like in absence of the lift created by the enthusiasm for AI. 3. 25% of the total value is in life sciences vs. 18% in volume; meaning life sciences rounds have been larger than other sectors. 4. Not surprisingly due to AI investments, tech industry led the way with 49% of the value. 5. The geographic hubs with most of the VC activity were in San Fran followed by NY, Boston and LA. (all three combined were still below the VC investment in San Fran alone) So, should we get excited? Maybe. If we rely on AI only, it won't sustain as some of these early investments will fail due to the intrinsic risk in our business. My bias is that once we clear two overhangs in the macro, we will be in the clear. First is the Fed rate tapering starting on Sep 18th which shows a 99% probability as per the options chain, and the second is an uncontested election. Once we pass these two macro hurdles, there is more than enough dry powder in the system that would be looking for highly differentiated therapies in unmet medical areas.

40

3 Comments

During the intense final rounds of MBB interviews at ISB, most candidates were on edge. Stress filled the air as people frantically flipped through notes, scribbled frameworks, or dissected their last case. But one person in our batch, let’s call him Alex, stood out for all the right reasons! While others spiralled into overthinking, Alex took a radically different approach during breaks. He stepped outside, walked around, and let his mind completely reset. No frantic cramming, no overanalysing—just a chance to recharge. This made all the difference! Alex walked into every case interview calm, focused, and ready to tackle whatever came their way. One of his interviewers even said, “You had a remarkable ability to stay present and composed.” Alex’s secret? He treated each interview like a fresh start, using breaks as a reset button, not a time to stress. It’s a simple yet powerful lesson: clear your head, and your best work will follow. If you’re preparing for consulting interviews, start practicing smarter with structured feedback at https://casepro.club. #CaseInterviewPrep #ConsultingCareers #MBBInterviews #InterviewSuccess #MBAJourney #ISBStories #ConsultingLife #ElitePerformance

6

1 Comment

Watch Abhishek Singh and Durga SaiSri Ambati from Everest Group as they discuss the shifts in #LifeSciences as organizations move from traditional CRMs to #CustomerExperience Platforms (#CXP) and its profound impact on #healthcare and patient outcomes. Gain insights into the strategic implications of the #Salesforce-#Veeva split, the expanding role of #CRM in patient-centered care, and how future platforms will transform engagement across the healthcare ecosystem. Watch: https://okt.to/cq2oDM

4

In their latest research, Gayatri B., Kara Ang Ke Qin and Zainul Jafferji laid out the status of #omnichannel scaling in #pharma across the geographies and capabilities. Some key learnings: (1) Omnichannel scaling has largely been limited to foundational capabilities and large, mature markets. (2) All pharma companies reported scaling at least one capability across M7 markets (the EU4, the U.K., Canada and Japan). (3) And 80% of respondents had scaled a data foundation, analytics and platform build to more than five markets It is also interesting to observe that there is no "one approach" to omnichannel that companies are taking across the board. for more - https://lnkd.in/dUBUThwz

23

4 Comments

🚀 PE Firms Increasing Pharma Exposure: Key Trends & Global Insights Private equity (PE) firms are significantly boosting their investments in the pharmaceutical sector, particularly in high-growth markets like India. Recently, Novartis announced a strategic review of its 70.68% stake in Novartis India, attracting interest from several global PE players like ChrysCapital, Kedaara Capital, Apollo Global Management, Inc., & Multiples Alternate Asset Management. 💡 Why Are PE Firms Boosting Their Pharma Exposure? 🔹 Stable and Resilient Sector: The pharma industry has shown resilience, especially during global economic slowdowns. The increasing demand for innovative therapies, particularly after the pandemic, makes the sector a compelling investment for PE firms looking for long-term value creation. 🔹 Shift Toward High-Margin Segments: Specialty pharmaceuticals, including oncology and biologics, are fast-growing areas that offer high returns. PE firms are particularly drawn to these high-margin segments for better investment outcomes. 🔹 India’s Pharma Strength: India remains a global leader in cost-efficient generic drug manufacturing and exports. Its growing role in R&D and clinical trials also makes it a key target for PE investments 💲 Why Pharma Companies Are Streamlining Through Divestitures? 🔸 Refocus on Core Areas: Pharma companies are divesting to concentrate on high-growth segments like specialty drugs and biologics​. 🔸 Boosting R&D: Divestments free up capital for innovation and R&D in cutting-edge therapeutic areas​. 🔸 Improving Profitability: Shedding non-core assets helps reduce complexity and enhance financial performance​. 🔸 Adapting to Market Changes: Post-COVID shifts and rising costs are driving companies to realign through strategic divestments 🌍 Some recent Global PE Investments in Pharma : Blackstone Life Sciences committed $750 million to back Moderna’s influenza program​. The Carlyle Group Group invested heavily in Piramal Pharma Ltd by acquiring a 20% stake for $490 million, reflecting a strategic move into India’s fast-growing healthcare space, particularly after the sector's pivotal role during the pandemic. KKR invested in Biosynth Carbosynth, a company crucial to drug manufacturing, underlining PE’s growing influence in the life sciences space. Advent International made headlines by acquiring a controlling stake in RA Chem Pharma LTD, further highlighting PE's growing appetite for Indian pharmaceutical assets. With global pharmaceutical leaders divesting non-core assets and focusing on strategic partnerships, the landscape is ripe for PE-backed investments, particularly in high-growth regions like India. The post-COVID momentum has only reinforced the value and necessity of these deals. #Pharma #PrivateEquity #Healthcare #Investment #COVID19 #GrowthOpportunities #MergersAndAcquisitions #India #SpecialtyPharma #GlobalMarkets Peak North

23

1 Comment

🌏 Understanding Technology Trends: Japan vs. India 🇯🇵🇮🇳 Exciting insights from Aditya Tallapragada, Founder of InterAKT & AKT Health Inc., on the unique tech landscapes of Japan and India! 🚀 Journey: From a mechanical engineer to leading health and IT innovations in Japan and India. Innovation in Japan: Strong academic culture, innovative startups, and a focus on solving local problems first before scaling globally. Challenges in India: Cultural gaps, slower adoption of new technologies, but immense opportunities, especially in IT and healthcare sectors. Future Goals: Moving from B2B to B2C, exploring blockchain, IoT, and AI to revolutionize healthcare and patient experiences. Key Takeaway: The importance of continuous learning, cultural understanding, and adaptability in the fast-paced tech world. Watch the full discussion below 📺 #Technology #Innovation #Healthcare #Blockchain #AI #IoT #GlobalTech

6

2 Comments

Diversity can be enhanced at every stage of the clinical trial process helping to advance healthcare equity. Check out RQM+'s latest white paper on diversity in clinical trials!

6

McKinsey & Company senior partner, Sathya Prathipati, talks about innovation niches that could be interesting for Indian firms. Yes, that includes #ADCs, #peptides etc. He also touched on the role of #AI in identifying the ‘known-knowns’ or even holistically scanning for abandoned assets with strong evidence of efficacy to identify new relevant opportunities. Plus, how India can build on the momentum across the wider #R&D ecosystem as big pharma expands their Global Capability Centers (GCCs) in the country. “The #GCC opportunity is a real here and now for India,” Prathipati said. https://lnkd.in/dChxTUiK

19

ZS Impact Live - Boston. Started off with a bang with keynote from Pratap Khedkar What are the high priority areas pharma executives are investing in across Commercial, R&D, and Supply Chain? Despite all the excitement about AI and upside potential, the vast majority of life sciences companies’ AI investments have failed to scale. To build a capability that is all about scaling AI impact, there are 6 enablers : Mindset, Process, Data, Talent, Adoption, and Trust.

166

1 Comment

A strategic guide for pharma leaders to win in Indian healthcare! As India’s pharmaceutical market is set to exceed $120 billion by 2030, we deep dive into the dynamic forces reshaping the sector. From rapid economic growth to digital health advancements, our latest report highlights India’s healthcare evolution and the success mantra for global Pharma companies in India. Read BCG’s report with OPPI India to discover the market outlook, vital learnings from other companies, strategic imperatives and success codes that will set you up for ‘Winning in Indian Healthcare': https://on.bcg.com/3Vgdo5x Authors: Priyanka Aggarwal, Anirudh Tara, Ishneh kochar, Aviruddh Jain, Anil Matai, Asawari Sathaye, Nayan Khanna hashtag #BCGIndia hashtag #BCGonHealthcare hashtag #IndianHealthcare hashtag #Healthcare hashtag #SuccessMantra Activate to view larger image,

123

5 Comments

Inadvertent privatization of healthcare? How the budget impacts all, you ask? a. Fewer investments into the maintenance of the already dilapidating healthcare assets, severely impacting the quality of patient care and disincentivizing doctors from practicing in an already lesser-than-market-paying career b. Lesser spending on maintaining/building new Government medical colleges, leading to cartelization of medical education in the hands of mushrooming private players c. Significant gap in out-of-pocket treatment costs between the private and public sectors The cascade effects of these are endless, from Women & Child Health, to Rural access to quality healthcare, leading to an already increased cost of living and so on. 'The 75th Round of the National Sample Survey revealed that there is a significant gap in out-of-pocket treatment costs between the private and public sectors. In 2017-18, the average medical cost of hospitalisation was Rs 4,452 in government hospitals and Rs 31,845 in private hospitals. In rural areas, the average out-of-pocket cost for non-childbirth hospitalisations was Rs 4,290 in government hospitals and Rs 27347 in private hospitals. These figures are higher in urban areas, with an average cost of Rs 4,837 in government hospitals and Rs 38,822 in private hospitals. Individuals also fund health expenditures through borrowings. The survey shows that 13.4% of the hospitalisation cases in rural areas and 8.5% in urban areas were financed by individuals through borrowings.' (https://bit.ly/3WjeBJa) Keep in mind that the budget also includes significant funding for water supply and sanitation at Rs 64,302.85 cr, an increase from the previous year's Rs 64,138.41 cr. (https://bit.ly/4daV3NQ) Ending with this, is a graph like this acceptable? Considering post-tax wages :) Sources: Graph - Business Insider India; Excerpt from Financial Express and Business Standard #Budget2024 #healthcare #India #development

52

4 Comments

As #JPM25 kicks off, here’s a quick snapshot of how the #MedTech industry fared in 2024—and what’s ahead in 2025: 1. Intensifying M&A Activity: Major deals (e.g. Johnson & Johnson acquiring Shockwave Medical for $13.1bn) reshaped the competitive landscape, with leading players focusing on high-growth segments through strategic mergers, divestitures, and portfolio refinements. 2. Supply Chain Overhaul: Persistent economic pressures prompted firms like Medtronic to expand regional manufacturing and Baxter to adopt dual-sourcing strategies—reinforced by AI-driven inventory management and predictive analytics to minimise risk. 3. Technological Breakthroughs: Innovations such as AI-enabled imaging (Siemens Healthineers) and advanced continuous glucose monitoring (Abbott) underpinned robust growth, driving R&D investment and accelerating clinical adoption. 4. Workforce and Cost Optimisation: Over 14,000 layoffs highlighted efforts to streamline operations and boost productivity through AI upskilling, process automation, and lean organisational structures. 5. Financial Pressures: Around 65% of top 200 MedTech stocks hovered near 52-week lows by year-end, intensifying focus on profitability and margin performance as key valuation levers. 6. Mixed Regional Performance: North America remained a hub for innovation, while Europe grappled with MDR costs and tender-based pricing. Asia-Pacific and emerging markets showed surging demand for accessible, AI-driven healthcare solutions. 7. AI-Powered Commercial Operations: Leading firms used analytics and AI to refine pricing models, expedite tender and RFP responses, and streamline sales processes—enabling quicker, data-driven decisions. 8. ESG and Sustainability Priorities: Rising calls for carbon neutrality, waste reduction, and local community engagement made sustainability a crucial tender and growth differentiator. 9. 2025 Outlook - Growth & Innovation: Market size is poised to exceed $650bn, with digital health projected to grow by 18–20% and minimally invasive devices by 12–15%, underpinned by continued R&D in breakthrough technologies. 10. Strategic Imperatives: C-level leaders must bolster supply chain resilience, embrace AI-driven commercial transformation, invest in high-potential segments, and develop talent strategies to maintain a competitive edge. Every year at Vamstar, we release our state-of-the-industry report at the JPM conference for the senior leaderships of the industry. While I’m unable to attend this time, here is a concise summary. If you'd like access to full report, please drop in the comments "Yes". #JPM25 #MedTech #HealthcareInnovation #DigitalHealth #AI #SupplyChain #Sustainability #MergersAndAcquisitions

22

6 Comments

Drew Houston is the co-founder & CEO of Dropbox. Under his leadership, Dropbox has grown from a simple idea to a service used by over 700 mn regd users globally, with a valuation exceeding $9 bn. Drew has led Dropbox through multiple phases, from explosive viral growth, to battling all the tech giants at once, to reinventing the company for the future of work. In our conversation, he opens up about: 📌 The 03 eras of Dropbox’s growth and evolution 📌 The challenges he’s faced over the past 18 yrs 📌 What he learned about himself 📌 How he’s been able to manage his psychology as a founder 📌 The importance of maintaining your learning curve 📌 Finding purpose beyond metrics & growth 📌 The micro, macro, & meta aspects of building companies Some takeaways: 📌 To stay ahead as a founder/CEO, you must keep your personal growth curve ahead of the company’s growth curve. To do so: 📌 Think systematically about what you’ll need to know 1, 2, and 5 years from now 📌 Build a community of peers at different stages (same stage, 2 yrs ahead, 5 yrs ahead, 20 yrs ahead) 📌 Read voraciously across disciplines & study historical parallels 📌 Run toward discomfort rather than away from it 📌 Managing your psychology is crucial for long-term success: 📌 Separate your identity from the company’s current state 📌 Build support systems (therapy, coaching, meditation) 📌 Recognize that challenge is inevitable but suffering is optional 📌 Find purpose beyond metrics & external validation 📌 Founder burnout happens when you’re stuck in “firefighting mode.” You need intentional time away from the day-to-day chaos to reflect on the bigger picture. Schedule “think weeks” or personal retreats to step off the treadmill & reorient your direction. It’s easy to be busy and unproductive—make sure your busywork isn’t getting in the way of the truly important stuff. 📌 The best leaders take 100% responsibility, even when it’s uncomfortable. Don’t rationalize your mistakes. Instead, reflect on what you could have done differently & own it. This mindset will prevent you from making the same mistakes & allow you to grow stronger as a leader. Watch out for the “seniority gap” as companies scale: 📌 Fast growth can lead to rapid internal promotions 📌 Without enough experienced leaders, teams solve known problems through trial & error 📌 Maintain a balance between high-potential talent & experienced leaders who can mentor them 📌 Recognize the business cycles around you & how the market changes. The strategies that worked y'day might not work today, so stay flexible. e.g, marketing today is shifting from traditional PR to more direct, social-media-driven approaches. Constantly reevaluate the “game” you’re playing & be ready to pivot with the times. 📌 Want attention? Figure out who needs to pay attention to you & work backward. Drew’s viral YC hack is a perfect e.g. he reverse engineered what Paul Graham was doing & created a video that caught his eye.

40

5 Comments

KKR is nearing a deal to acquire Healthcare Global Enterprises Limited Global Enterprises Ltd (HCG), India's largest specialty cancer care hospital chain, from CVC  The transaction, expected to close in early 2025, highlights KKR's return to the Indian healthcare market after a two-year hiatus. As part of the acquisition, KKR plans to increase its stake through an open offer, potentially gaining control and driving further growth in India's cancer care sector. The deal follows a successful period of expansion for HCG, which is well-positioned for continued growth in the sector. #Healthcare #PrivateEquity #CancerCare #HCG #KKR #Investment #MergersAndAcquisitions #IndianHealthcare #HospitalSector #GrowthOpportunities

6

India’s healthcare and life sciences sectors are set for transformative growth, with market sizes poised to double over the next 5-7 years. As 2025 approaches, the focus will shift toward digital adoption, strategic M&A, and increased R&D investments. Investor confidence remains robust, with significant inflows into pharma services, MedTech, and niche segments like IVF and eyecare. With the support of initiatives like 'Make in India,' the sector is well-positioned to adapt to global pressures while driving innovation and expansion into new markets. Resilience, adaptability, and innovation will define the path forward. hashtag #PwCDeals #TogetherWeFuture #HealthcareDeals

124

2 Comments